newsfilter
← Latest News
PR Newswire·

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

– Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma – – Received confirmation from the FDA that the planned Phase